ES2741379T3 - Método de uso de la expresión génica para determinar la probabilidad de resultado clínico de cáncer renal - Google Patents

Método de uso de la expresión génica para determinar la probabilidad de resultado clínico de cáncer renal Download PDF

Info

Publication number
ES2741379T3
ES2741379T3 ES17153152T ES17153152T ES2741379T3 ES 2741379 T3 ES2741379 T3 ES 2741379T3 ES 17153152 T ES17153152 T ES 17153152T ES 17153152 T ES17153152 T ES 17153152T ES 2741379 T3 ES2741379 T3 ES 2741379T3
Authority
ES
Spain
Prior art keywords
expression
level
genes
lmnb1
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17153152T
Other languages
English (en)
Spanish (es)
Inventor
Steven Shak
Audrey Goddard
Dejan Knezevic
Joffre Baker
Michael C Kiefer
Tara Maddala
Frederick L Baehner
Wayne Cowens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genomic Health Inc
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Application granted granted Critical
Publication of ES2741379T3 publication Critical patent/ES2741379T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G01N33/57525—
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Probability & Statistics with Applications (AREA)
  • Algebra (AREA)
  • Software Systems (AREA)
  • Mathematical Physics (AREA)
ES17153152T 2010-01-11 2011-01-07 Método de uso de la expresión génica para determinar la probabilidad de resultado clínico de cáncer renal Active ES2741379T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29403810P 2010-01-11 2010-01-11
US34623010P 2010-05-19 2010-05-19

Publications (1)

Publication Number Publication Date
ES2741379T3 true ES2741379T3 (es) 2020-02-10

Family

ID=44258831

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17153152T Active ES2741379T3 (es) 2010-01-11 2011-01-07 Método de uso de la expresión génica para determinar la probabilidad de resultado clínico de cáncer renal
ES20210111T Active ES3027507T3 (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES20210111T Active ES3027507T3 (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Country Status (12)

Country Link
US (4) US9551034B2 (enExample)
EP (5) EP2524055A4 (enExample)
JP (5) JP6286124B2 (enExample)
AU (1) AU2011203977B2 (enExample)
CA (3) CA2783858C (enExample)
DK (1) DK3178944T3 (enExample)
ES (2) ES2741379T3 (enExample)
IL (6) IL219978A (enExample)
MX (3) MX341866B (enExample)
NZ (4) NZ600268A (enExample)
SG (1) SG181806A1 (enExample)
WO (1) WO2011085263A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524055A4 (en) 2010-01-11 2013-06-05 Genomic Health Inc METHOD FOR THE USE OF GENE EXPRESSION FOR DETERMINING THE PROBABILITY OF CLINICAL EXERCISE OF KIDNEY CANCER
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
MX350533B (es) 2010-08-13 2017-09-08 Somalogic Inc Biomarcadores de cancer pancreatico y usos de los mismos.
WO2013016673A2 (en) * 2011-07-27 2013-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of dpep1 and tpx2 expression for evaluating treatment or survival time of patients with pancreatic ductal adenocarcinoma
US20130065782A1 (en) * 2011-08-22 2013-03-14 Somalogic, Inc. Renal Cell Carcinoma Biomarkers and Uses Thereof
HK1212389A1 (en) 2011-10-24 2016-06-10 Signalchem Lifesciences Corporation Carbonic anhydrase ix-related markers and use thereof
WO2013116144A1 (en) 2012-01-31 2013-08-08 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
EP3825420A1 (en) * 2013-05-30 2021-05-26 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
WO2015050500A1 (en) 2013-09-17 2015-04-09 Agency For Science, Technology And Research Multigene assay for prognosis of renal cancer
US10731163B2 (en) * 2014-09-02 2020-08-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Oligonucleotide targeted to the A20-3′ untranslated region
JP6638128B2 (ja) * 2014-10-30 2020-01-29 公立大学法人福島県立医科大学 腎がんの悪性度の検査マーカー及び検査方法
US20180044736A1 (en) * 2015-02-03 2018-02-15 Cedars-Sinai Medical Center Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer
GB201616912D0 (en) 2016-10-05 2016-11-16 University Of East Anglia Classification of cancer
PL3589754T3 (pl) 2017-03-01 2023-10-09 F. Hoffmann-La Roche Ag Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
WO2018161027A1 (en) * 2017-03-03 2018-09-07 Oregon State University Antisense antibacterial compounds and methods
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
US11335464B2 (en) * 2018-01-12 2022-05-17 Siemens Medical Solutions Usa, Inc. Integrated precision medicine by combining quantitative imaging techniques with quantitative genomics for improved decision making
EP3833785A1 (en) * 2018-08-10 2021-06-16 Omniseq, Inc. Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade
WO2020085936A1 (ru) * 2018-10-24 2020-04-30 Общество С Ограниченной Ответственностью "Онкобокс" Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
IL284700B2 (en) 2019-01-23 2025-10-01 Regeneron Pharma Treating eye conditions with angiopoietin-like 7 inhibitors
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
WO2021030604A1 (en) * 2019-08-14 2021-02-18 University Of Massachusetts Urinary rna signatures in renal cell carcinoma (rcc)
KR20230148819A (ko) 2021-02-26 2023-10-25 리제너론 파마슈티칼스 인코포레이티드 글루코코르티코이드 및 안지오포이에틴-유사 7 (angptl7) 억제제를 이용한 염증의 치료
CN113025716A (zh) * 2021-03-02 2021-06-25 北京大学第一医院 一种用于人肿瘤分级的基因组合及其用途
CN113817816A (zh) * 2021-10-08 2021-12-21 济南艾迪康医学检验中心有限公司 检测epas1基因突变的引物、试剂盒和方法
WO2023080900A1 (en) * 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
CN118711678B (zh) * 2024-08-22 2025-12-12 暨南大学附属第一医院（广州华侨医院） 一种肾透明细胞肿瘤预测方法、装置、设备及存储介质

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US7135314B1 (en) * 1997-04-17 2006-11-14 Cell Therapeutics, Inc. Human phosphatidic acid phosphatase
DK1246917T3 (da) * 2000-01-13 2009-06-08 Genentech Inc Humane Stra6-polypeptider
DE10126344A1 (de) * 2000-07-14 2002-01-24 Max Planck Gesellschaft Apoptose-induzierende DNA-Sequenzen
AU2001294842A1 (en) * 2000-09-28 2002-04-08 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
WO2002074237A2 (en) * 2001-03-19 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002079411A2 (en) * 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
JP2005500832A (ja) 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド 乳癌患者の診断および予後
US7470509B2 (en) 2002-02-08 2008-12-30 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
US7081340B2 (en) 2002-03-13 2006-07-25 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
AU2003288918A1 (en) * 2002-10-04 2004-05-04 Van Andel Research Institute Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
BR0316111A (pt) 2002-11-21 2005-09-13 Wyeth Corp Métodos para diagnosticar rcc e outros tumores sólidos
WO2004097052A2 (en) 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
JP4680898B2 (ja) 2003-06-24 2011-05-11 ジェノミック ヘルス， インコーポレイテッド 癌再発の可能性の予測
BRPI0412110A (pt) 2003-07-02 2006-11-21 Novartis Ag genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos
US20050002904A1 (en) * 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
EP3330875B1 (en) 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
WO2005024603A2 (en) 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
JP2005211023A (ja) * 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
ES2550614T3 (es) 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
US20070224596A1 (en) * 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
JP2008500057A (ja) * 2004-05-27 2008-01-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｉｍｐｄｈ経路の阻害をモニタリングするためのバイオマーカー
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US20080119367A1 (en) * 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
AU2006210794A1 (en) * 2005-02-01 2006-08-10 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Biomarkers for tissue status
BRPI0608429A2 (pt) * 2005-02-18 2009-12-29 Wyeth Corp método e kit para prognóstico ou avaliação da eficácia do tratamento de um tumor sólido em um paciente de interesse; e método para a identificação de marcadores que sejam prognósticos de um tumor sólido
US20090186024A1 (en) 2005-05-13 2009-07-23 Nevins Joseph R Gene Expression Signatures for Oncogenic Pathway Deregulation
WO2006124022A1 (en) * 2005-05-13 2006-11-23 Vanandel Research Institute Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma
US20070037186A1 (en) * 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
CA2611728A1 (en) * 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070105133A1 (en) * 2005-06-13 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1893581B1 (en) * 2005-06-15 2010-01-27 Pfizer Limited Substituted arylpyrazoles for use against parasitites
CA2621070A1 (en) * 2005-09-02 2007-03-08 Toray Industries, Inc. Composition and method for diagnosing kidney cancer and estimating kidney cancer patient's prognosis
WO2007030882A1 (en) 2005-09-14 2007-03-22 Human Genetic Signatures Pty Ltd Assay for a health state
EP2982688A3 (en) * 2005-09-30 2016-05-25 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
CA2631236C (en) 2005-12-01 2019-10-29 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20070141066A1 (en) 2005-12-16 2007-06-21 Genentech, Inc. Method for Diagnosing, Prognosing and Treating Glioma
WO2007146668A2 (en) * 2006-06-06 2007-12-21 University Of Massachusetts Use of imp3 as a prognostic marker for cancer
WO2008021183A2 (en) * 2006-08-10 2008-02-21 Millennium Pharmaceuticals, Inc. For the identification, assessment, and treatment of patients with cancer therapy
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
WO2008083098A1 (en) 2006-12-27 2008-07-10 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
US20080286273A1 (en) 2007-05-02 2008-11-20 Siemens Medical Solutions Usa, Inc. Knowledge-Based Proliferation Signatures and Methods of Use
EP1990417A1 (en) 2007-05-11 2008-11-12 Universität Bayreuth Archaeal plasmid vector system
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
CA3153682A1 (en) 2008-11-17 2010-05-20 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
CA2766703A1 (en) * 2009-06-26 2010-12-29 Noviogendix Research B.V. Molecular markers in kidney cancer
CA2776751C (en) 2009-11-23 2019-07-02 Genomic Health, Inc. Methods to predict clinical outcome of cancer
EP2524055A4 (en) 2010-01-11 2013-06-05 Genomic Health Inc METHOD FOR THE USE OF GENE EXPRESSION FOR DETERMINING THE PROBABILITY OF CLINICAL EXERCISE OF KIDNEY CANCER
EP2721179A4 (en) 2011-06-16 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L BIOMARKER COMPOSITIONS AND METHOD THEREFOR
US20130065782A1 (en) 2011-08-22 2013-03-14 Somalogic, Inc. Renal Cell Carcinoma Biomarkers and Uses Thereof

Also Published As

Publication number Publication date
IL256335B (en) 2018-12-31
US20240096451A1 (en) 2024-03-21
CA3128103A1 (en) 2011-07-14
MX341866B (es) 2016-09-06
IL251635A0 (en) 2017-06-29
EP3831964A2 (en) 2021-06-09
DK3178944T3 (da) 2019-08-12
EP3178944A3 (en) 2017-09-13
US20170121780A1 (en) 2017-05-04
IL270151B (en) 2021-03-25
CA2783858C (en) 2021-09-14
IL251635B (en) 2018-04-30
JP7385630B2 (ja) 2023-11-22
JP2021177761A (ja) 2021-11-18
WO2011085263A3 (en) 2012-01-12
IL262100A (en) 2018-11-29
SG181806A1 (en) 2012-07-30
NZ600268A (en) 2014-08-29
IL262100B (en) 2019-11-28
US9551034B2 (en) 2017-01-24
US20210166790A1 (en) 2021-06-03
WO2011085263A2 (en) 2011-07-14
IL280689B (en) 2022-01-01
CA2783858A1 (en) 2011-07-14
EP3561078A1 (en) 2019-10-30
US20220051755A9 (en) 2022-02-17
EP3178944A2 (en) 2017-06-14
EP3178944B1 (en) 2019-05-15
JP2016174600A (ja) 2016-10-06
US10892038B2 (en) 2021-01-12
AU2011203977A1 (en) 2012-06-21
JP2017148059A (ja) 2017-08-31
IL219978A0 (en) 2012-07-31
EP2524055A4 (en) 2013-06-05
JP6546214B2 (ja) 2019-07-17
EP3831964A3 (en) 2021-10-20
JP6286124B2 (ja) 2018-02-28
CA3256492A1 (en) 2025-11-29
JP7307602B2 (ja) 2023-07-12
IL280689A (en) 2021-03-25
NZ705645A (en) 2016-05-27
MX2020009704A (es) 2020-10-07
MX2012007882A (es) 2012-08-03
NZ719474A (en) 2018-07-27
EP3831964B1 (en) 2025-04-16
EP2524055A2 (en) 2012-11-21
EP3029155A2 (en) 2016-06-08
AU2011203977B2 (en) 2015-02-05
US12412642B2 (en) 2025-09-09
MX375138B (es) 2025-03-06
JP2019162150A (ja) 2019-09-26
EP3029155A3 (en) 2016-08-31
NZ617003A (en) 2015-04-24
US11776664B2 (en) 2023-10-03
ES3027507T3 (en) 2025-06-16
JP2013516195A (ja) 2013-05-13
US20110171633A1 (en) 2011-07-14
IL219978A (en) 2017-04-30
CA3128103C (en) 2025-11-18

Similar Documents

Publication Publication Date Title
ES2741379T3 (es) Método de uso de la expresión génica para determinar la probabilidad de resultado clínico de cáncer renal
JP7042784B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
ES2735993T3 (es) Métodos para predecir el resultado clínico del cáncer
JP5297202B2 (ja) 結腸直腸癌の予後のための遺伝子発現マーカー
US11551782B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
US20110287958A1 (en) Method for Using Gene Expression to Determine Colorectal Tumor Stage
AU2015202116B2 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ752676B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
NZ711680B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer